Journal Article
Unraveling the impact of miRNAs on gouty arthritis: diagnostic significance and therapeutic opportunities
Sherif S. Abdel Mageed; Hanan Elimam; Ahmed E. Elesawy; Ahmed I. Abulsoud; Ahmed Amr Raouf; Manar Mohammed El Tabaa; Osama A. Mohammed; Mohamed Bakr Zaki; Mai A. Abd-Elmawla; Walaa A. El-Dakroury; Safwat Abdelhady Mangoura; Mahmoud A. Elrebehy; Mohammed S. Elballal; Aya A. Mohamed; Alaa Ashraf; Mustafa Ahmed Abdel-Reheim; Ali M. S. Eleragi; Hussein Abdellatif; Ahmed S. Doghish
Naunyn-Schmiedeberg's Archives of Pharmacology · Vol. 398, Issue 4 · pp. 3433-3450 · 2025
Abstract
Gouty arthritis is a prevalent inflammatory illness. Gout attacks begin when there is an imbalance in the body’s uric acid metabolism, which leads to urate buildup and the development of the ailment. A family of conserved, short non-coding RNAs known as microRNAs (miRNAs) can regulate post-transcriptional protein synthesis by attaching to the 3′ untranslated region (UTR) of messenger RNA (mRNA). An increasing amount of research is pointing to miRNAs as potential players in several inflammatory diseases, including gouty arthritis. miRNAs may influence the progression of the disease by regulating immune function and inflammatory responses. This review mainly focused on miRNAs and how they contribute to gouty arthritis. It also looked at how miRNAs could be used as diagnostic, prognostic, and potential therapeutic targets.